{
  "nctId": "NCT04845971",
  "briefTitle": "Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia",
  "officialTitle": "Phase II Clinical Trial Evaluating Efficacy and Safety of Oral Immunotherapy With Third Generation Gc Protein Derived Macrophage Activating Factor (GcMAF) in Hospitalized Patients With COVID-19 Pneumonia: the COral-MAF1 Trial",
  "protocolDocument": {
    "nctId": "NCT04845971",
    "filename": "Prot_SAP_ICF_001.pdf",
    "label": "Study Protocol, Statistical Analysis Plan, and Informed Consent Form",
    "date": "2021-02-23",
    "uploadDate": "2021-04-14T11:46",
    "size": 3561553,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04845971/document/Prot_SAP_ICF_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": true
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 97,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-11-05",
    "completionDate": "2021-06-30",
    "primaryCompletionDate": "2021-04-30",
    "firstSubmitDate": "2020-11-17",
    "firstPostDate": "2021-04-15"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Adults (≥ 18 years of age);\n* signed informed consent by any patient capable of giving consent, or, when the patient is not capable of giving consent, by his or her legal/authorized representative or according to local guidelines;\n* patients clinically diagnosed with SARS-CoV-2 virus by PCR or by other approved diagnostic methodology;\n* hospitalized with COVID-19-induced pneumonia evidenced by chest x-ray or CT scan with pulmonary infiltrates;\n* patients having a PAO2/FIO2 ratio \\> 250 mmHg;\n* well-selected patients having a PAO2/FIO2 ratio ≤ 250 mmHg that, in the investigator's judgment, doesn't preclude the patient's safe participation in and completion of the study;\n* patients being able to swallow.\n\nExclusion Criteria:\n\n* Proportion of hospitalized patients requiring invasive mechanical ventilation at the time of hospital admission (patients requiring non-invasive mechanical ventilation are eligible);\n* uncontrolled systemic infection (other than COVID-19);\n* hypersensitivity to the active substance or to any of the excipients of the experimental drug, including known allergy to dairy product;\n* any serious medical condition or abnormality of clinical laboratory tests;\n* in the opinion of the investigator, progression to death is imminent and highly likely within the next 24 hours, irrespective of the provision of treatments;\n* current participation in any other interventional investigational trials;\n* pregnant or breastfeeding woman;\n* concurrent malignancy requiring chemotherapy;\n* renal insufficiency;\n* all types of disability.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "the rate of transfer to the intensive care unit (ICU)",
        "description": "the proportion of hospitalized patients requiring intensive care management because of worsening respiratory function (PaO2/FiO2 ratio \\<150 mmHg) and/or development of multi-organ dysfunction and/or other clinical conditions needing invasive mechanical ventilation Given that 26% of patients required intensive care unit treatment, the purpose of this trial is to achieve a reduction of at least 50% of this value with an overall rate of transfer to the ICU of 13%.",
        "timeFrame": "28 days or until discharge"
      }
    ],
    "secondary": [
      {
        "measure": "Changes from baseline to subsequent timepoints (when available) in terms of percentage of lung involvement (lung consolidation, ground glass opacities and disease free).",
        "description": "CT visual quantitative evaluation will be based on summing up the acute lung inflammatory lesions involving each lobe, which was scored as 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%), or 4 (76-100%), respectively. In particular, an early reduction from 85% to 50% in imaging progression on chest CT at day 7 will be evaluated, as a surrogate endpoint",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "duration of hospital stay",
        "description": "expressed in days",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "days on non-invasive ventilation",
        "description": "expressed in days",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "time to reduction of FiO2 > 25%",
        "description": "expressed in days",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "days with use of supplemental O2",
        "description": "expressed in days",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "discharge rate at day 28",
        "description": "expressed in days",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "clinical evolution",
        "description": "proportion of patients with COVID-19 symptoms worsening.",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "time to resolution of fever",
        "description": "time to resolution of fever (for at least 48 hours) in absence of antipyretics, or discharge, whichever is sooner in the 4-week period after study treatment. Resolution of fever is defined as body temperature: ≤36.6°C (axilla) or ≤37.2 °C (oral), or ≤37.8 °C (rectal or tympanic). Fever is defined as defined as body temperature \\> 37.4°C \\[axilla\\], or \\> 38.0 °C \\[oral\\], or \\>38.4°C \\[rectal or tympanic\\];",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "progression of respiratory failure",
        "description": "progression of respiratory failure as evaluated by the PaO2/FiO2 ratio",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "implementation of supplemental oxygen",
        "description": "proportion of patients requiring implementation of supplemental oxygen during the 28-day period",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes from baseline in white blood cell count (WBC)",
        "description": "changes from baseline in white blood cell count (WBC)",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in hemoglobin level",
        "description": "changes from baseline in hemoglobin",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in platelet count",
        "description": "changes from baseline in platelets",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in CRP levels",
        "description": "changes from baseline in CRP",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in ESR value",
        "description": "changes from baseline in ESR",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in LDH levels",
        "description": "changes from baseline in LDH",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in procalcitonin value",
        "description": "changes from baseline in procalcitonin",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in IL-6 levels",
        "description": "changes from baseline in IL-6",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in TNF-α levels",
        "description": "changes from baseline in TNF-α",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in D-dimer",
        "description": "changes from baseline in D-dimer",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "changes in fibrinogen levels",
        "description": "changes from baseline in fibrinogen",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "MAF precursor activity of serum Gc protein",
        "description": "changes from baseline in MAF precursor activity of serum Gc protein as marker for response to treatment",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "serum nagalase activity",
        "description": "changes from baseline in serum nagalase activity, as marker for response to treatment;",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "viral loads detected in nasopharyngeal swabs",
        "description": "kinetic changes of viral loads detected in nasopharyngeal swabs",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "Serious Adverse Events (SAE) and Adverse Drug Reaction (ADR) (expected and unexpected)",
        "description": "number of Serious Adverse Events (SAE) and Adverse Drug Reaction (ADR) (expected and unexpected)",
        "timeFrame": "28 days or until discharge"
      },
      {
        "measure": "patient compliance with treatment.",
        "description": "proportion of patients",
        "timeFrame": "28 days or until discharge"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 26,
      "otherCount": 0,
      "totalCount": 27
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:45.822Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}